Moderna Inc (MRNA)
Payables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Cost of revenue | US$ in thousands | 1,464,000 | 4,693,000 | 5,416,000 | 2,617,000 | 7,933 |
Payables | US$ in thousands | — | — | — | — | — |
Payables turnover | — | — | — | — | — |
December 31, 2024 calculation
Payables turnover = Cost of revenue ÷ Payables
= $1,464,000K ÷ $—K
= —
The payables turnover ratio for Moderna Inc is not provided for the years 2020, 2021, 2022, 2023, and 2024. The lack of this data makes it difficult to assess the efficiency with which the company is managing its accounts payable and paying off its suppliers. A higher payables turnover ratio typically indicates a company is paying its suppliers more quickly, while a lower ratio may suggest the opposite. In the absence of this information, it is advised to monitor Moderna Inc's financial performance indicators closely in the future to better understand its payables turnover efficiency.
Peer comparison
Dec 31, 2024
Company name
Symbol
Payables turnover
Moderna Inc
MRNA
—
ADMA Biologics Inc
ADMA
10.23
Amgen Inc
AMGN
—
Bio-Techne Corp
TECH
25.82
Biogen Inc
BIIB
12.10
Gilead Sciences Inc
GILD
—
Halozyme Therapeutics Inc
HALO
—
Krystal Biotech Inc
KRYS
22.81
Neurocrine Biosciences Inc
NBIX
—
Repligen Corporation
RGEN
—
Vericel Corp Ord
VCEL
—